Kolexia
Chollet Philippe Médecine interne
Chollet Philippe
Médecine interne
Centre Jean-Perrin
Clermont-Ferrand, France
48 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs colorectales Tumeurs du sein triple-négatives Tumeurs de la prostate Carcinome canalaire du sein Récidive tumorale locale Tumeurs prostatiques résistantes à la castration Invasion tumorale

Collaborateurs

Voir plus
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France
Durando Xavier
Durando Xavier
Centre Jean-Perrin, Clermont-Ferrand, France
Van Praagh Isabelle
Van Praagh Isabelle
Centre Jean-Perrin, Clermont-Ferrand, France
Penault-Llorca Frederique
Penault-Llorca Frederique
Centre Jean-Perrin, Clermont-Ferrand, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Cancer medicine   05 mars 2021
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial.
International journal of cancer   03 décembre 2020
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Cancer medicine   22 avril 2020
Optimizing FOLFIRINOX tolerability in patients with colorectal cancer through dosing irinotecan in the morning for men and in the afternoon for women.
2020 Gastrointestinal Cancers Symposium   04 février 2020
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer: The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
Essai Clinique (Eisai)   17 décembre 2019
Improvement in adherence to Capecitabine and Lapatinib by way of a therapeutic education program.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   22 novembre 2019
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer: An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.
Essai Clinique (Centre Jean-Perrin)   20 juillet 2018
Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC)
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): Final results from an international trial (EORTC 05011)
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Oncology   16 janvier 2016